HetrombopagAlternative Names: Hetrombopag olamine; SHR 8735 olamine
Latest Information Update: 11 May 2016
Price : $50
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Mechanism of Action Thrombopoietin stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Idiopathic thrombocytopenic purpura
Most Recent Events
- 11 May 2016 Chemical structure information added
- 01 Nov 2015 Jiangsu HengRui Medicine initiates enrolment in a phase I trial in Idiopathic thrombocytopenic purpura in China (PO) NCT02614846)
- 01 Apr 2014 Jiangsu HengRui Medicine completes a phase I trial in Healthy volunteers in China (NCT02409394)